Skip to main content
SpringerLink
Log in

Clinical Pharmacology and Therapeuticsof Antidepressants

  • Chapter
  • First Online:
Pharmacotherapy of Depression

Abstract

An understanding of the clinical pharmacology of antidepressant agents is essential to optimal prescribing. The following chapter outlines general principles that influence prescribing, and then discusses specific subgroups of antidepressants. There is no generally accepted classification scheme for antidepressants, and current groupings reflect marketing, the history of development, and pharmacologic effects. We use the following terminology in our discussion: selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), cyclic antidepressants, mixed action agents, selective norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and alternative (non-traditional) antidepressants. Readers should keep in mind that there is no classification scheme that accurately reflects the actions of all the drug classes, and we have chosen a compromise classification system that is based on terms commonly used in clinical settings.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mrazek D. Psychiatric pharmacogenomics. Oxford: Oxford University Press; 2010.

    Google Scholar 

  2. Horstmann S, Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacol Ther. 2009;124(1):57–73.

    Article  CAS  PubMed  Google Scholar 

  3. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008;57(2):203–9.

    Article  CAS  PubMed  Google Scholar 

  4. Pariante CM. Glucocorticoid receptor function in vitro in patients with major depression. Stress. 2004;7(4):209–19.

    Article  CAS  PubMed  Google Scholar 

  5. Pariante CM. The role of multi-drug resistance p-glycoprotein in glucocorticoid function: studies in animals and relevance in humans. Eur J Pharmacol. 2008;583(2–3):263–71.

    Article  CAS  PubMed  Google Scholar 

  6. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004;36(12):1319–25.

    Article  CAS  PubMed  Google Scholar 

  7. Zimmerman M, Posternak MA, Chelminski I. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res. 2004;38(6):577–82.

    Article  PubMed  Google Scholar 

  8. Hawley CJ, Gale TM, Sivakumaran T. Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord. 2002;72(2):177–84.

    Article  CAS  PubMed  Google Scholar 

  9. Kirchheiner J, Lorch R, Lebedeva E, Seeringer A, Roots I, Sasse J, et al. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics. 2008;9(7):841–6.

    Article  CAS  PubMed  Google Scholar 

  10. Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 2009;9(4):225–33.

    Article  CAS  PubMed  Google Scholar 

  11. Papiol S, Arias B, Gasto C, Gutierrez B, Catalan R, Fananas L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord. 2007;104(1–3):83–90.

    Article  CAS  PubMed  Google Scholar 

  12. Tsai SJ, Hong CJ, Chen TJ, Yu YW. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(8):1097–8.

    Article  CAS  PubMed  Google Scholar 

  13. Ising M, Depping AM, Siebertz A, Lucae S, Unschuld PG, Kloiber S, et al. Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur J Neurosci. 2008;28(2):389–98.

    Article  PubMed  Google Scholar 

  14. Laje G, Perlis RH, Rush AJ, McMahon FJ. Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv. 2009;60(11):1446–57.

    Article  PubMed  Google Scholar 

  15. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry. 2007;164(8):1181–8.

    Article  PubMed  Google Scholar 

  16. Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology. 2010;35(3):727–40.

    Article  CAS  PubMed  Google Scholar 

  17. Perlis RH, Patrick A, Smoller JW, Wang PS. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology. 2009;34(10):2227–36.

    Article  CAS  PubMed  Google Scholar 

  18. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009;66(9):966–75.

    Article  CAS  PubMed  Google Scholar 

  19. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–58.

    Article  CAS  PubMed  Google Scholar 

  20. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47–53.

    Article  CAS  PubMed  Google Scholar 

  21. Dunner DL. Acute and maintenance treatment of chronic depression. J Clin Psychiatry. 2001;62(Suppl 6):10–6.

    CAS  PubMed  Google Scholar 

  22. Stewart JW, McGrath PJ, Quitkin FM. Can mildly depressed outpatients with atypical depression benefit from antidepressants? Am J Psychiatry. 1992;149(5):615–9.

    CAS  PubMed  Google Scholar 

  23. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackiem HA, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003;26(2):457–94.

    Article  PubMed  Google Scholar 

  24. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19(2):179–200.

    Article  CAS  PubMed  Google Scholar 

  25. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry. 1991;52(Suppl):28–34.

    PubMed  Google Scholar 

  26. Rush AJ, Warden D, Wisniewski SR, Fava M, Trivedi MH, Gaynes BN, et al. STAR*D: revising conventional wisdom. CNS Drugs. 2009;23(8):627–47.

    PubMed  Google Scholar 

  27. Kennedy N, Abbott R, Paykel ES. Longitudinal syndromal and sub-syndromal symptoms after severe depression: 10-year follow-up study. Br J Psychiatry. 2004;184:330–6.

    Article  PubMed  Google Scholar 

  28. Kennedy N, Paykel ES. Residual symptoms at remission from depression: impact on long-term outcome. J Affect Disord. 2004;80(2–3):135–44.

    Article  CAS  PubMed  Google Scholar 

  29. Kennedy N, Paykel ES. Treatment and response in refractory depression: results from a specialist affective disorders service. J Affect Disord. 2004;81(1):49–53.

    Article  CAS  PubMed  Google Scholar 

  30. DeVane CL. Differential pharmacology of newer antidepressants. J Clin Psychiatry. 1998;59(Suppl 20):85–93.

    CAS  PubMed  Google Scholar 

  31. Ban TA. Pharmacotherapy of depression: a historical analysis. J Neural Transm. 2001;108(6):707–16.

    Article  CAS  PubMed  Google Scholar 

  32. Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry. 1999;60(Suppl 4):4–11; discussion 2–3.

    Google Scholar 

  33. Sampson SM. Treating depression with selective serotonin reuptake inhibitors: a practical approach. Mayo Clin Proc. 2001;76(7):739–44.

    Article  CAS  PubMed  Google Scholar 

  34. Goldberg JF. New drugs in psychiatry. Emerg Med Clin North Am. 2000;18(2):211–31; viii.

    Google Scholar 

  35. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders. I. Basic pharmacology. J Psychopharmacol. 1998;12(3 Suppl B):S5–20.

    CAS  PubMed  Google Scholar 

  36. Fuller RW, Snoddy HD, Krushinski JH, Robertson DW. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology. 1992;31(10):997–1000.

    Article  CAS  PubMed  Google Scholar 

  37. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr. 2002;7(Suppl 1):40–4.

    PubMed  Google Scholar 

  38. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Therap. 2003;305(1):197–204.

    Article  CAS  Google Scholar 

  39. Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology. 2000;22(4):380–7.

    Article  CAS  PubMed  Google Scholar 

  40. Uhr M, Graucer MT. abc1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res. 2003;37:179–85.

    Article  PubMed  Google Scholar 

  41. Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ. P-glycoprotein interactions of nefazodone and trazodone in cell culture. J Clin Pharmacol. 2001;41(7):708–14.

    Article  CAS  PubMed  Google Scholar 

  42. Quitkin FM, Petkova E, McGrath PJ, Taylor B, Beasley C, Stewart J, et al. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry. 2003;160(4):734–40.

    Article  PubMed  Google Scholar 

  43. Goodwin GM. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry. 1996;57(Suppl 4):9–13.

    CAS  PubMed  Google Scholar 

  44. Gilmor ML, Owens MJ, Nemeroff CB. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry. 2002;159(10):1702–10.

    Article  PubMed  Google Scholar 

  45. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatment: implications for the therapeutic response in major depression. J Clin Psychopharmacol. 1987;7:24S–35.

    Article  CAS  PubMed  Google Scholar 

  46. Banasr M, Hery M, Printemps R, Daszuta A. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology. 2004;29(3):450–60.

    Article  CAS  PubMed  Google Scholar 

  47. Greene J, Banasr M, Lee B, Warner-Schmidt J, Duman RS. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology. 2009;34(11):2459–68.

    Article  CAS  PubMed  Google Scholar 

  48. Pinna G, Costa E, Guidotti A. SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Curr Opin Pharmacol. 2009;9(1):24–30.

    Article  CAS  PubMed  Google Scholar 

  49. Benamansour S, Owens WA, Cecchi M, Morilak DA, Frazer A. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci. 2002;22(15):6766–72.

    Google Scholar 

  50. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994;51(3):248–51.

    Article  CAS  PubMed  Google Scholar 

  51. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol. 1995;15(3):217–22.

    Article  CAS  PubMed  Google Scholar 

  52. Berman RM, Darnell AM, Miller HL, Anand A, Charney DS. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 1997;154(12):37–43.

    CAS  PubMed  Google Scholar 

  53. Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 1997;349(9065):1594–7.

    Article  CAS  PubMed  Google Scholar 

  54. Maes M, Libbrecht I, van Hunsel F, Campens D, Meltzer HY. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol. 1999;19(2):177–82.

    Article  CAS  PubMed  Google Scholar 

  55. Stein MB, Sareen J, Hami S, Chao J. Pindolol potentation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001;158(10):1725–7.

    Article  CAS  PubMed  Google Scholar 

  56. Rabiner EA, Bhagwagar Z, Gunn RN, Sargent PA, Bench CJ, Cowen PJ, et al. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatry. 2001;158(12):2080–2.

    Article  CAS  PubMed  Google Scholar 

  57. Wu S, Comings DE. A common C-1018G polymorphism in the human 5-HT1A receptor gene. Psychiatr Genet. 1999;9(2):105–6.

    Article  CAS  PubMed  Google Scholar 

  58. Nishiguchi N, Shirakawa O, Ono H, Nishimura A, Nushida H, Ueno Y, et al. Lack of an association between 5-HT1A receptor gene structural polymorphisms and suicide victims. Am J Med Genet. 2002;114(4):423–5.

    Article  PubMed  Google Scholar 

  59. Isaac MT, Tome MB. Pindolol-paroxetine combination. Am J Psychiatry. 1997;154(12):1790–1.

    CAS  PubMed  Google Scholar 

  60. Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry. 1998;59(Suppl 5):16–23.

    CAS  PubMed  Google Scholar 

  61. Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d’Experimentation Psychopharmacologique. Am J Psychiatry. 1998;155(10):1346–51.

    CAS  PubMed  Google Scholar 

  62. Taylor D. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses. Br J Psychiatry. 1995;167(5):575–80.

    Article  CAS  PubMed  Google Scholar 

  63. Ereshefsky L, Riesenman C, Lam YWF. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. J Clin Psychiatry. 1996;57(Suppl 8):17–25.

    CAS  PubMed  Google Scholar 

  64. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153(3):311–20.

    CAS  PubMed  Google Scholar 

  65. Baumann P. Care of depression in the elderly: comparative pharmacokinetics of SSRIs. Int Clin Psychopharmacol. 1998;13(Suppl 5):S35–43.

    Article  PubMed  Google Scholar 

  66. Baker GB, Fang J, Sinha S, Coutts RT. Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants. Neurosci Biobehav Rev. 1998;22(2):325–33.

    Article  CAS  PubMed  Google Scholar 

  67. Johnson MD, Newkirk G, White JR, Jr. Clinically significant drug interactions. Postgrad Med. 1999;105(2):193–5, 200, 5–6 passim.

    Google Scholar 

  68. Rickels K, Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry. 1990;51(Suppl B):9–12.

    Google Scholar 

  69. Frazer A. Antidepressants. J Clin Psychiatry. 1997;58(Suppl 6):9–25.

    CAS  PubMed  Google Scholar 

  70. Benbow SJ, Gill G. Drug points: paroxetine and hepatotoxicity. Br Med J. 1997;314(7091):1387.

    Article  CAS  Google Scholar 

  71. Cai Q, Benson MA, Talbot TJ, Devadas G, Swanson HJ, Olson JL, et al. Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc. 1999;74(7):692–4.

    Article  CAS  PubMed  Google Scholar 

  72. Garcia-Pando A, Garcia del Pozo J, Sanchez A, et al. Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry. 2002;63:135–7.

    Article  CAS  Google Scholar 

  73. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol. 1998;12(2):192–214.

    Article  CAS  PubMed  Google Scholar 

  74. Walsh MT, Dinan TG. Selective serotonin reuptake inhibitors and violence: a review of the available evidence. Acta Psychiatr Scand. 2001;104(2):84–91.

    Article  CAS  PubMed  Google Scholar 

  75. Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol. 1997;17(5):377–89.

    Article  CAS  PubMed  Google Scholar 

  76. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry. 1994;164(4):549–50.

    Article  CAS  PubMed  Google Scholar 

  77. Stoll AL, Mayer PV, Kolbrener M, Goldstein E, Suplit B, Lucier J, et al. Antidepressant-associated mania: a controlled comparison with spontaneous mania. Am J Psychiatry. 1994;151(11):1642–5.

    CAS  PubMed  Google Scholar 

  78. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990;147(2):207–10.

    CAS  PubMed  Google Scholar 

  79. Fava M, Rosenbaum JF. Suicidality and fluoxetine: is there a relationship? J Clin Psychiatry. 1991;51:267–85.

    Google Scholar 

  80. Tollefson GD, Rampey AH, Jr., Beasley CM, Jr., Enas GG, Potvin JH. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. Journal of Clinical Psychopharmacology. 1994;14(3):163–9.

    Article  CAS  PubMed  Google Scholar 

  81. Muller-Oerlinghausen B, Berghofer A. Antidepressants and suicidal risk. J Clin Psychiatry. 1999;60(Suppl 2):94–9; discussion 111–6.

    Google Scholar 

  82. Tueth MJ. Revisiting fluoxetine (Proxac) and suicidal preoccupations. J Emerg Med. 1994;12(5):685–7.

    Article  CAS  PubMed  Google Scholar 

  83. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705–13.

    CAS  PubMed  Google Scholar 

  84. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol. 1997;17(3):208–21.

    Article  CAS  PubMed  Google Scholar 

  85. Dams R, Benijts TH, Lambert WE, Van Bocxlaer JF, Van Varenbergh D, Van Peteghem C, et al. A fatal case of serotonin syndrome after combined moclobemide and citalopram intoxication. J Anal Toxicol. 2001;25(2):147–51.

    CAS  PubMed  Google Scholar 

  86. DeSilva KE, Le Flore DB, Marston BJ, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS. 2001;15(10):1281–5.

    Article  CAS  PubMed  Google Scholar 

  87. Holsboer F. Neuroendocrinology of mood disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven; 1995. p. 957–69.

    Google Scholar 

  88. Inder WJ, Prickett TC, Mulder RT, Donald RA, Joyce PR. Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. Psychopharmacology (Berl). 2001;156(1):73–8.

    Article  CAS  Google Scholar 

  89. Barclay TS, Lee AJ. Citalopram-associated SIADH. Ann Pharmacother. 2002;36:1558–63.

    Article  PubMed  Google Scholar 

  90. Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999;156(8):1170–6.

    CAS  PubMed  Google Scholar 

  91. Harvey BH, Bouwer CD. Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Clin Neuropharmacol. 2000;23(2):90–7.

    Article  CAS  PubMed  Google Scholar 

  92. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(Suppl 11):37–41.

    CAS  PubMed  Google Scholar 

  93. Alderman CP, Seshadri P, Ben-Tovim DI. Effects of serotonin reuptake inhibitors on hemostasis. Ann Pharmacother. 1996;30:1232–4.

    CAS  PubMed  Google Scholar 

  94. Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci. 2007;9(1):47–59.

    PubMed  Google Scholar 

  95. Balon R, Yeragani VK, Pohl R, et al. Sexual dysfunction during antidepressant treatment. J Clin Psychiatry. 1993;54:209–12.

    CAS  PubMed  Google Scholar 

  96. Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry. 1994;55(9):406–13.

    CAS  PubMed  Google Scholar 

  97. Margolese HC, Assalian P. Sexual side effects of antidepressants: a review. J Sex Marital Ther. 1996;22(3):209–17.

    Article  CAS  PubMed  Google Scholar 

  98. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19(1):67–85.

    Article  CAS  PubMed  Google Scholar 

  99. Fava M, Rankin MA. Sexual functioning and SSRIs. J Clin Psychiatry. 2002;63(Suppl 5):13–6.

    PubMed  Google Scholar 

  100. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calcedo A, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997;23(3):176–94.

    Article  CAS  PubMed  Google Scholar 

  101. Herman JB, Brotman AW, Pollack MH, Falk WE, Biederman J, Rosenbaum JF. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry. 1990;51(1):25–7.

    CAS  PubMed  Google Scholar 

  102. Patterson WM. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry. 1993;54(2):71.

    CAS  PubMed  Google Scholar 

  103. Rothschild AJ. Sexual side effects of antidepressants. J Clin Psychiatry. 2000;61(Suppl 11):28–36.

    CAS  PubMed  Google Scholar 

  104. Fava M, Rankin MA, Alpert JE, Nierenberg AA, Worthington JJ. An open trial of oral sildenfalin in antidepressant-induced sexual dysfunction. Psychother Psychosom. 1998;67(6):328–31.

    Article  CAS  PubMed  Google Scholar 

  105. Nurnberg HG, Lauriello J, Hensley PL, Parker LM, Keith SJ. Sildenafil for sexual dysfunction in women taking antidepressants. Am J Psychiatry. 1999;156(10):1664.

    CAS  PubMed  Google Scholar 

  106. Nurnberg HG, Seidman SN, Gelenberg AJ, Fava M, Rosen R, Shabsigh R. Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. Urology. 2002;60(2 Suppl 2):58–66.

    Article  PubMed  Google Scholar 

  107. Walker PW, Cole JO, Gardner EA, Hughes AR, Johnston JA, Batey SR, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry. 1993;54(12):459–65.

    CAS  PubMed  Google Scholar 

  108. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry. 1995;152(10):1514–6.

    CAS  PubMed  Google Scholar 

  109. Haddad P. The SSRI discontinuation syndrome. J Psychopharmacol. 1998;12(3):305–13.

    Article  CAS  PubMed  Google Scholar 

  110. Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic critieria. J Psychiatr Neurosci. 2000;25(3):255–61.

    CAS  Google Scholar 

  111. DeBattista C, Schatzberg AF. Physical sysmptoms associated with paroxetine withdrawal [letters to the editor]. Am J Psychiatry. 1995;152(8):1235–6.

    CAS  PubMed  Google Scholar 

  112. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry. 1998;59(Suppl 15):42–8.

    CAS  PubMed  Google Scholar 

  113. Ostrom M, Eriksson A, Thorson J, Spigset O. Fatal overdose with citalopram. Lancet. 1996;348(9023):339–40.

    CAS  PubMed  Google Scholar 

  114. Glassman AH. Citalopram toxicity. Lancet. 1997;350:818.

    Article  CAS  PubMed  Google Scholar 

  115. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998;279(8):609–10.

    Article  CAS  PubMed  Google Scholar 

  116. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007;80(1):18–27.

    Article  CAS  PubMed  Google Scholar 

  117. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol. 2008;83(1):68–76.

    Article  CAS  PubMed  Google Scholar 

  118. Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics. 2010;125(3):e600–8.

    Article  PubMed  Google Scholar 

  119. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579–87.

    Article  CAS  PubMed  Google Scholar 

  120. Ravindran AV, Guelfi JD, Lane RM, Cassano GB. Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. J Clin Psychiatry. 2000;61(11):821–7.

    Article  CAS  PubMed  Google Scholar 

  121. Leonard HL. New developments in the treatment of obsessive-compulsive disorder. J Clin Psychiatry. 1997;58(Suppl 14):39–47.

    CAS  PubMed  Google Scholar 

  122. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry. 1999;60(2):101–6.

    Article  CAS  PubMed  Google Scholar 

  123. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, et al. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study.Br J Psychiatry. 1995;167(3):374–9.

    Article  CAS  PubMed  Google Scholar 

  124. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry. 1995;152(9):1368–71.

    CAS  PubMed  Google Scholar 

  125. Davidson JRT. Pharmacology of social anxiety disorder. J Clin Psychiatry. 1998;59(Suppl 17):47–51.

    CAS  Google Scholar 

  126. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry. 2002;63(1):66–74.

    Article  CAS  PubMed  Google Scholar 

  127. Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding W. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry. 1990;147(7):876–81.

    CAS  PubMed  Google Scholar 

  128. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. New Engl J Med. 1995;332(23):1529–34.

    Article  CAS  PubMed  Google Scholar 

  129. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62(5):350–7.

    Article  CAS  PubMed  Google Scholar 

  130. Davidson JRT. Biological therapies for posttraumatic stress disorder: an overview. J Clin Psychiatry. 1997;58(9):29–32.

    PubMed  Google Scholar 

  131. Cheer SM, Goa KL. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs. 2001;61(1):81–110.

    Article  CAS  PubMed  Google Scholar 

  132. Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, Jr., et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701–9.

    Article  CAS  PubMed  Google Scholar 

  133. Pettinati HM. The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. J Clin Psychiatry. 2001;62(Suppl 20):26–31.

    CAS  PubMed  Google Scholar 

  134. Pettinati HM, Volpicelli JR, Luck G, Kranzler HR, Rukstalis MR, Cnaan A. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol. 2001;21(2):143–53.

    Article  CAS  PubMed  Google Scholar 

  135. Davis JM, Wang Z, Janicak PG. A quantitative analysis of clinical drug trials for the treatment of affective disorders. Psychopharmacol Bull. 1993;129:175–81.

    Google Scholar 

  136. McGrath PJ, Stewart JW, Janal MN, Petkova E, Quitkin FM, Klein DF. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry. 2000;157(3):344–50.

    Article  CAS  PubMed  Google Scholar 

  137. Kasper S, Fuger J, Moller HJ. Comparative efficacy of antidepressants. Drugs. 1992;43(Suppl 2):11–23.

    Article  PubMed  Google Scholar 

  138. Amsterdam JD. Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. J Psychopharmacol. 1998;12(3 Suppl B):S99–111.

    Google Scholar 

  139. Verkes RJ, Van der Mast RC, Hengeveld MW, Tuyl JP, Zwinderman AH, Van Kempen GM. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am J Psychiatry. 1998;155(4):543–7.

    CAS  PubMed  Google Scholar 

  140. Byrne SE, Rothschild AJ. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J Clin Psychiatry. 1998;59:279–88.

    Article  CAS  PubMed  Google Scholar 

  141. Fava M, Rappe SM, Pava JA, Nierenberg AA, Alpert JE, Rosenbaum JF. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry. 1995;56(2):52–5.

    CAS  PubMed  Google Scholar 

  142. Kuhn R. The treatment of depressive states with G22355 (imipramine hydrochloride). Am J Psychiatry. 1958;115:459–64.

    CAS  PubMed  Google Scholar 

  143. Klerman GL, Cole JP. Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacol Rev. 1965;17:101–41.

    CAS  PubMed  Google Scholar 

  144. Frommer DA, Kulig KW, Marx JA, Rumack B. Tricyclic antidepressant overdose. A review. JAMA. 1987;257(4):521–6.

    Article  CAS  PubMed  Google Scholar 

  145. Rudorfer MV, Potter WZ. Metabolism of tricyclic antidepressants. Cell Mol Neurobiol. 1999;19(3):373–409.

    Article  CAS  PubMed  Google Scholar 

  146. Wilens TE, Biederman J, Baldessarini RJ, Puopolo PR, Flood JG. Developmental changes in serum concentrations of desipramine and 2-hydroxydesipramine during treatment with desipramine. J Am Acad Child Adolesc Psychiatry. 1992;31(4):691–8.

    Article  CAS  PubMed  Google Scholar 

  147. Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis TL, et al. A Double-Blind, Placebo-Controlled Trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010;167:668–75.

    Article  PubMed  Google Scholar 

  148. Blackwell B. Adverse effects of antidepressant drugs; part 1: MAOIs and tricyclics. Drugs. 1981;21:201–19.

    Article  CAS  PubMed  Google Scholar 

  149. Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowers MB, Jr. Major adverse reactions during desipramine treatment: relationship to plasma drug concentrations, concomitant antipsychotic treatment, and patient characteristics. Arch Gen Psychiatry. 1982;39(9):1055–61.

    Article  CAS  PubMed  Google Scholar 

  150. Glassman AH, Bigger JT, Jr. Cardiovascular effects of therapeutic doses of tricyclic antidepressants. A review. Arch Gen Psychiatry. 1981;38(7):815–20.

    Article  CAS  PubMed  Google Scholar 

  151. Glassman AH. Cardiovascular effects of antidepressant drugs: updated. Int Clin Psychopharmacol. 1998;13(Suppl 5):S25–30.

    Article  PubMed  Google Scholar 

  152. Roose SP, Glassman AH. Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. J Clin Psychiatry. 1994;55(Suppl A):83–7; discussion 8–9, 98–100.

    Google Scholar 

  153. Vohra J, Burrows GD, Sloman G. Assessment of cardiovascular side effects of therapeutic doses of tricyclic anti-depressant drugs. Aust N Z J Med. 1975;5(1):7–11.

    Article  CAS  PubMed  Google Scholar 

  154. Roose SP, Glassman AH, Siris SG, Walsh BT, Bruno RL, Wright LB. Comparison of imipramine- and nortriptyline-induced orthostatic hypotension: a meaningful difference. J Clin Psychopharmacol. 1981;1(5):316–9.

    Article  CAS  PubMed  Google Scholar 

  155. Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol. 2003;23(1):58–77.

    Article  CAS  PubMed  Google Scholar 

  156. Maltzberg B. Mortality among patients with involutional melancholia. Am J Psychiatry. 1937;93:1231–8.

    Google Scholar 

  157. Williams RB, Jr., Sherter C. Cardiac complications of tricyclic antidepressant therapy. Ann Intern Med. 1971;74(3):395–8.

    PubMed  Google Scholar 

  158. Bigger JT, Jr., Giardina EGV, Perel JM, Kantor SJ, Glassman AH. Cardiac antiarrhythmic effect of imipramine hydrochloride. N Engl J Med. 1977;296(4):206–8.

    Article  CAS  PubMed  Google Scholar 

  159. Roose SP, Glassman AH, Giardina EG, Walsh BT, Woodring S, Bigger JT. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry. 1987;44(3):273–5.

    Article  CAS  PubMed  Google Scholar 

  160. Dalack GW, Roose SP, Glassman AH. Tricyclics and heart failure. Am J Psychiatry. 1991;148(11):1601.

    CAS  PubMed  Google Scholar 

  161. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406–12.

    Article  Google Scholar 

  162. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992;327:227–33.

    Article  Google Scholar 

  163. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG. Is doxepin a safer tricyclic for the heart? J Clin Psychiatry. 1991;52(8):338–41.

    CAS  PubMed  Google Scholar 

  164. Monteiro WO, Noshirvani HF, Marks IM, Lelliott PT. Anorgasmia from clomipramine in obsessive-compulsive disorder. A controlled trial. Br J Psychiatry. 1987;151:107–12.

    Article  CAS  PubMed  Google Scholar 

  165. Callaham M, Kassel D. Epidemiology of fatal tricyclic antidepressant ingestion: implications for management. Ann Emerg Med. 1985;14:1–9.

    Article  CAS  PubMed  Google Scholar 

  166. Kulig K, Rumack BH, Sullivan JB, Jr., Brandt H, Spyker DA, Duffy JP, et al. Amoxapine overdose. Coma and seizures without cardiotoxic effects. JAMA. 1982;248(9):1092–4.

    Article  CAS  PubMed  Google Scholar 

  167. Litovitz TL, Troutman WG. Amoxapine overdose. Seizures and fatalities. JAMA. 1983;250(8):1069–71.

    Article  CAS  PubMed  Google Scholar 

  168. Knudsen K, Heath A. Effects of self poisoning with maprotiline. Br Med J (Clin Res Ed). 1984;288(6417):601–3.

    Article  CAS  Google Scholar 

  169. Olfson M, Klerman GL. Trends in the prescription of antidepressants by office-based psychiatrists. Am J Psychiatry. 1993;150(4):571–7.

    CAS  PubMed  Google Scholar 

  170. Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomized controlled trials. Br J Psychiatry. 2001;178:129–44.

    Article  CAS  PubMed  Google Scholar 

  171. Boyce P, Judd F. The place for the tricyclic antidepressants in the treatment of depression. Aust N Z J Psychiatry. 1999;33:323–7.

    Article  CAS  PubMed  Google Scholar 

  172. Vestergaard P, Gram LF, Kragh-Sorensen P, Bech P, Reisby N, Bolwig TG. Therapeutic potentials of recently introduced antidepressants. Danish University Antidepressant Group. Psychopharmacol Ser. 1993;10:190–8.

    CAS  PubMed  Google Scholar 

  173. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry. 1994;151(12):1735–9.

    CAS  PubMed  Google Scholar 

  174. Perry PJ. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord. 1996;39(1):1–6.

    Article  CAS  PubMed  Google Scholar 

  175. Biederman J, Thisted RA, Greenhill LL, Ryan ND. Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. J Clin Psychiatry. 1995;56(3):87–93.

    CAS  PubMed  Google Scholar 

  176. Spencer T, Biederman J, Wilens T, Harding M, O’Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35(4):409–32.

    Article  CAS  PubMed  Google Scholar 

  177. Wilens TE, Biederman J, Prince J, Spencer TJ, Faraone SV, Warburton R, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 1996;153(9):1147–53.

    CAS  PubMed  Google Scholar 

  178. Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157(9):1445–52.

    Article  CAS  PubMed  Google Scholar 

  179. Quitkin FM, Stewart JW, McGrath PJ. Gender differences in treatment response. Am J Psychiatry. 2001;158(9):1531–3.

    Article  CAS  PubMed  Google Scholar 

  180. Quitkin FM, Stewart JW, McGrath PJ, Taylor BP, Tisminetzky MS, Petkova E, et al. Are there differences between women’s and men’s antidepressant responses? Am J Psychiatry. 2002;159(11):1848–54.

    Article  PubMed  Google Scholar 

  181. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63(4):308–15.

    Article  CAS  PubMed  Google Scholar 

  182. Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord. 1998;51(3):237–54.

    Article  CAS  PubMed  Google Scholar 

  183. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger GC, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56(9):395–401.

    CAS  PubMed  Google Scholar 

  184. Settle EC, Jr. Bupropion sustained release: side effect profile. J Clin Psychiatry. 1998;59(Suppl 4):32–6.

    CAS  PubMed  Google Scholar 

  185. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 1995;56(Suppl 6):12–21.

    PubMed  Google Scholar 

  186. Lineberry TW, Peters GE, Jr., Bostwick JM. Bupropion-induced erythema multiforme. Mayo Clin Proc. 2001;76(6):664–6.

    CAS  PubMed  Google Scholar 

  187. DeVane CL, Grothe DR, Smith SL. Pharmacology of antidepressants: focus on nefazodone. J Clin Psychiatry. 2002;63(Suppl 1):10–7.

    CAS  PubMed  Google Scholar 

  188. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs. 1995;49(2):280–94.

    Article  CAS  PubMed  Google Scholar 

  189. Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety. 1998;7(Suppl 1):24–32.

    Article  PubMed  Google Scholar 

  190. Nelson JC. Safety and tolerability of the new antidepressants. J Clin Psychiatry. 1997;58(Suppl 6):26–31.

    CAS  PubMed  Google Scholar 

  191. Schweizer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry. 1994;55(3):104–8.

    CAS  PubMed  Google Scholar 

  192. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry. 1997;154(12):1760–2.

    CAS  PubMed  Google Scholar 

  193. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, et al. Prenancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry. 2001;158(10):1728–30.

    Article  CAS  PubMed  Google Scholar 

  194. Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull. 1990;26(3):311–5.

    CAS  PubMed  Google Scholar 

  195. Lader MH. Tolerability and safety: essentials in antidepressant pharmacotherapy. J Clin Psychiatry. 1996;57(Suppl 2):39–44.

    CAS  PubMed  Google Scholar 

  196. Warner MD, Peabody CA, Whiteford HA, Hollister LE. Trazodone and priapism. J Clin Psychiatry. 1987;48(6):244–5.

    CAS  PubMed  Google Scholar 

  197. Stewart DE. Hepatic adverse reactions associated with nefazodone. Can J Psychiatry. 2002;47(4):375–7.

    PubMed  Google Scholar 

  198. Ehrentraut S, Rothenhausler HB, Gerbes AL, Rau HG, Thiel M, Schirren CA, et al. Acute liver failutre in nefazodone therapy? A case report [article in German]. Nervenarzt. 2002;73(7):686–9.

    Article  CAS  PubMed  Google Scholar 

  199. de Boer T, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, ORG 3770 and its enantiomers. Neuropharmacology. 1988;27(4):399–408.

    Article  PubMed  Google Scholar 

  200. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57(Suppl 4):19–25.

    CAS  PubMed  Google Scholar 

  201. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet. 2000;355(9207):911–8.

    Article  CAS  PubMed  Google Scholar 

  202. Stahl SM. Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry. 1998;59(Suppl 4):5–14.

    CAS  PubMed  Google Scholar 

  203. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM. 2003;86(5):369–74.

    Article  Google Scholar 

  204. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ. 2002;325(7376):1332–3.

    Article  PubMed  Google Scholar 

  205. Bremner JD, Wingard P, Walshe TA. Safety of mirtazapine in overdose. J Clin Psychiatry. 1998;59:233–5.

    Article  CAS  PubMed  Google Scholar 

  206. Benson BE, Mathiason M, Dahl B, Smith K, Foley MM, Easom LA, et al. Toxicities and outcomes associated with nefazodone poisoning: an analysis of 1,338 exposures. Am J Emerg Med. 2000;18(5):587–92.

    Article  CAS  PubMed  Google Scholar 

  207. de Meester A, Carbutti G, Gabriel L, Jacques JM. Fatal overdose with trazodone: case report and literature review. Acta Clin Belg. 2001;56(4):258–61.

    PubMed  Google Scholar 

  208. Harris CR, Gualtieri J, Stark G. Fatal bupropion overdose. J Toxicol Clin Toxicol. 1997;35(3):321–4.

    Article  CAS  PubMed  Google Scholar 

  209. Storrow AB. Bupropion overdose and seizure. Am J Emerg Med. 1994;12(2):183–4.

    Article  CAS  PubMed  Google Scholar 

  210. Spiller HA, Ramoska EA, Krenzelok EP, Sheen SR, Borys DJ, Villalobos D, et al. Bupropion overdose: a 3-year multi-center retrospective analysis. Am J Emerg Med. 1994;12(1):43–5.

    Article  CAS  PubMed  Google Scholar 

  211. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med. 2001;135(6):423–33.

    CAS  PubMed  Google Scholar 

  212. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology. 2001;57(9):1583–8.

    Article  CAS  PubMed  Google Scholar 

  213. Dostert P, Benedetti MS, Poggest I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol. 1997;7(Suppl 1):S23–35.

    Article  CAS  PubMed  Google Scholar 

  214. Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000;39(6):413–27.

    Article  CAS  PubMed  Google Scholar 

  215. Ohman D, Cherma MD, Norlander B, Bengstosson F. Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine. Ther Drug Monit. 2003;25(2):174–82.

    Article  PubMed  Google Scholar 

  216. Burrows GD, Maguire KP, Norman TR. Antidepressant efficiacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry. 1998;59(Suppl 14):4–7.

    CAS  PubMed  Google Scholar 

  217. Schatzberg AF. Clinical efficacy of reboxetine in major depression. J Clin Psychiatry. 2000;61(Suppl 10):31–8.

    CAS  PubMed  Google Scholar 

  218. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol. 2000;20(1):28–34.

    Article  CAS  PubMed  Google Scholar 

  219. Fleishaker JC, Francom SF, Herman BD, Knuth DW, Azie NE. Lack of effect of reboxetine on cardiac repolarization. Clin Pharmacol Ther. 2001;70(3):261–9.

    Article  CAS  PubMed  Google Scholar 

  220. Andreoli V, Caillard V, Deo R, Rybakowski JK, Versiani M. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.J Clin Psychopharmacol. 2002;22(4):393–9.

    Article  CAS  PubMed  Google Scholar 

  221. Montgomery S, Fuerguson JM, Schwartz GE. The antidepressant efficacy of reboxetine in patients with severe depression. J Clin Psychopharmacol. 2003;23(1):45–50.

    Article  CAS  PubMed  Google Scholar 

  222. Harmer CJ, O’Sullivan U, Favaron E, Massey-Chase R, Ayres R, Reinecke A, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry. 2009;166(10):1178–84.

    Article  PubMed  Google Scholar 

  223. Bruhl AB, Kaffenberger T, Herwig U. Serotonergic and noradrenergic modulation of emotion processing by single dose antidepressants. Neuropsychopharmacology. 2010;35(2):521–33.

    Article  CAS  PubMed  Google Scholar 

  224. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol. 2001;21(5):516–21.

    Article  CAS  PubMed  Google Scholar 

  225. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, et al. An open trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry. 2002;52(5):386–92.

    Article  CAS  PubMed  Google Scholar 

  226. Krishnan KR. Clinical experience with substance P receptor (NK1) antagonists in depression. J Clin Psychiatry. 2003;63(Suppl 11):25–9.

    Google Scholar 

  227. Rimon R, Le Greves P, Nyberg F, Heikkila L, Salmela L, Terenius L. Elevation of substance P-like peptides in the CSF of psychiatric patients. Biol Psychiatry. 1984;19(4):509–16.

    CAS  PubMed  Google Scholar 

  228. McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010;25(2):95–102.

    Article  CAS  PubMed  Google Scholar 

  229. Fishback JA, Robson MJ, Xu YT, Matsumoto RR. Sigma receptors: potential targets for a new class of antidepressant drug. Pharmacol Ther. 2010;127:271–82.

    Article  CAS  PubMed  Google Scholar 

  230. Fox H, Gibas J. Synthetic tuberculostats. VII. Monoalkyl derivatives of isonicotinylhydrazine. J Org Chem. 1953;18:994–1002.

    Article  CAS  Google Scholar 

  231. Selikoff IJ, Robitzek EH, Orenstein GG. Treatment of pulmonary tuberculosis with hydrazine derivatives of isonicotinic acid. JAMA. 1952;150:973–80.

    Article  CAS  Google Scholar 

  232. Loomers HP, Saunders JC, Kline NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep. 1957;8:129–41.

    Google Scholar 

  233. Kline NS. Clinical experience with iproniazid (MARSILID). J Clin Exp Pyschopathol. 1958;19(Suppl 1):72–8.

    CAS  Google Scholar 

  234. Zeller EA, Barsky JR, Fouts W, et al. Influence of isonicotinic acid hydrazide (INH) and 1-isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes. Experientia. 1952;8:349–50.

    Article  CAS  Google Scholar 

  235. Weinstock M, Gorodetsky E, Wang RH, Gross A, Weinreb O, Youdim MBH. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits. Neuropharmacology. 2002;43(6):999–1005.

    Article  CAS  PubMed  Google Scholar 

  236. Baker GB, Urichuk LJ, McKenna KF, Kennedy SH. Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol. 1999;19(3):411–26.

    Article  CAS  PubMed  Google Scholar 

  237. Youdim MB, Aronson JK, Blau K, Green AR, Grahame-Smith DG. Tranylcypromine (‘Parnate’) overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med. 1979;9(2):377–82.

    Article  CAS  PubMed  Google Scholar 

  238. Sherry-McKenna RL, Baker GB, Mousseau DD, Coutts RT, Dewhurst WG. 4-methyoxytranylcypromine, a monoamine oxidase inhibitor: effects on biogenic amines in rat brain following chronic administration. Biol Psychiatry. 1992;31(9):881–8.

    CAS  PubMed  Google Scholar 

  239. Sherry RL, Rauw G, McKenna KF, Paetsch PR, Coutts RT, Baker GB. Failure to detect amphetamine or 1-amino-3-phenylpropane in humans or rats receiving the MAO inhibitor tranylcypromine. J Affect Disord. 2000;61(1–2):23–9.

    Article  CAS  PubMed  Google Scholar 

  240. Lang A, Geissler HE, Mutschler E. Determination and comparison of the plasma and urine concentrations in men given tranylcypromine stereoisomers [article in German]. Arzneimittelforschung. 1979;29(1):154–7.

    CAS  PubMed  Google Scholar 

  241. Spahn-Langguth H, Hahn G, Mutschler E, Mohrke W, Langguth P. Enantiospecific high-performance liquid chromatographic assay with fluoroscence detection for the monoamine oxidase ihibitor tranylcypromine and its applicability in pharmacokinetic studies.J Chromatogr. 1992;584(2):229–37.

    Article  CAS  PubMed  Google Scholar 

  242. Livingston MG, Livingston HM. Monoamine oxidase inhibitors. An update on drug interactions. Drug Saf. 1996;14(4):219–27.

    Article  CAS  PubMed  Google Scholar 

  243. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20(3):226–47.

    Article  CAS  PubMed  Google Scholar 

  244. Guelfi JD, Payan C, Fermanian J, Pedarriosse AM, Manfredi R. Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial. Br J Psychiatry. 1992;160:519–24.

    Article  CAS  PubMed  Google Scholar 

  245. Hilton SE, Maradit H, Moller HJ. Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur Arch Psychiatr Clin Neurosci. 1997;247(3):113–9.

    Article  CAS  Google Scholar 

  246. van Vliet IM, Westenberg HG, Den Boer JA. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study. Psychopharmacology (Berl). 1993;112(4):483–9.

    Article  Google Scholar 

  247. Haefely W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, et al. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology (Berl). 1992;106(Suppl):S6–14.

    Article  CAS  Google Scholar 

  248. McGrath PJ, Stewart JW, Nunes EV, Ocepek-Welikson K, Rabkin JG, Quitkin FM, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry. 1993;150(1):118–23.

    CAS  PubMed  Google Scholar 

  249. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry. 1988;45(2):129–37.

    Article  CAS  PubMed  Google Scholar 

  250. McGrath PJ, Stewart JW, Harrison WM, Ocepek-Welikson K, Rabkin JG, Nunes EN, et al. Predictive value of symptoms of atypical depression for differential drug treatment outcome. J Clin Psychopharmacol. 1992;12(3):197–202.

    Article  CAS  PubMed  Google Scholar 

  251. Vallejo J, Gasto C, Catalan R, Salamero M. Double-blind study of imipramine versus phenelzine in melancholias and dysthymic disorders. Br J Psychiatry. 1987;151:639–42.

    Article  CAS  PubMed  Google Scholar 

  252. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry. 1991;148(7):910–6.

    CAS  PubMed  Google Scholar 

  253. Georgotas A, McCue RE, Hapworth W, Friedman E, Kim OM, Welkowitz J, et al. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry. 1986;21(12):1155–66.

    Article  CAS  PubMed  Google Scholar 

  254. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Tricamo E, Wager SG, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication. Arch Gen Psychiatry. 1990;47(10):935–41.

    Article  CAS  PubMed  Google Scholar 

  255. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12(3):185–219.

    Article  CAS  PubMed  Google Scholar 

  256. Price LH, Charney DS, Heninger GR. Efficacy of lithium-tranylcypromine treatment in refractory depression. Am J Psychiatry. 1985;142(5):619–23.

    CAS  PubMed  Google Scholar 

  257. Roose SP, Glassman AH, Walsh BT, Woodring S. Tricyclic nonresponders: phenomenology and treatment. Am J Psychiatry. 1986;143(3):345–8.

    CAS  PubMed  Google Scholar 

  258. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry. 1992;149(2):195–8.

    CAS  PubMed  Google Scholar 

  259. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry. 1992;49(4):290–300.

    CAS  PubMed  Google Scholar 

  260. Stein G. Drug treatment of the personality disorders. Br J Psychiatry. 1992;161:167–84.

    Article  CAS  PubMed  Google Scholar 

  261. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry. 1993;150(12):1843–8.

    CAS  PubMed  Google Scholar 

  262. Nurnberg HG, Levine PE. Spontaneous remission of MAOI-induced anorgasmia. Am J Psychiatry. 1987;144(6):805–7.

    CAS  PubMed  Google Scholar 

  263. Asatoor AM, Levi AJ, Milne MD. Tranylcypromine and cheese (letters to the editor). Lancet. 1963;2:733–4.

    Article  CAS  PubMed  Google Scholar 

  264. Blackwell B, Marley E, Price J, et al. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry. 1967;113:349–65.

    Article  CAS  PubMed  Google Scholar 

  265. Hyman S. Toxic side effects of psychotropic medications and their management. In: Hyman S, Tesar G, editors. Manual of psychiatric emergencies. 3rd ed. Boston: Little Brown 1994. p. 204–17; 304–22.

    Google Scholar 

  266. Insel TR, Roy BF, Cohen RM, Murphy DL. Possible development of the serotonin syndrome in man. Am J Psychiatry. 1982;139(7):954–5.

    CAS  PubMed  Google Scholar 

  267. Creelman WL, Ciraulo DA. Monoamine oxidase inhibitors (MAOIS). In: Ciraulo DA, Shader RI, Greenblatt DJ, Creelman WL, editors. Drug interactions in psychiatry. 2nd ed. Baltimore, MD: Williams & Wilkins; 1995. p. 430.

    Google Scholar 

  268. Linden CH, Rumack BH, Strehlke C. Monoamine oxidase inhibitor overdose. Ann Emerg Med. 1984;13(12):1137–44.

    Article  CAS  PubMed  Google Scholar 

  269. Vartzopoulos D, Krull F. Dependence on monoamine oxidase inhibitors in high dose.Br J Psychiatry. 1991;158:856–7.

    Article  CAS  PubMed  Google Scholar 

  270. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven; 1995. p. 1081.

    Google Scholar 

  271. Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(Suppl 13):23–9.

    PubMed  Google Scholar 

  272. Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry. 2000;61(Suppl 2):10–2.

    PubMed  Google Scholar 

  273. Carpenter LL, Jocic Z, Hall JM, Rasmussen SA, Price LH. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry. 1999;60(1):45–9.

    Article  CAS  PubMed  Google Scholar 

  274. Debonnel G, Gobbi G, Turcotte J, et al., editors. The α2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater antidepressant response: a double-blind controlled study. 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; San Juan, Puerto Rico.

    Google Scholar 

  275. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of mirtazapine augmentation for refractory depression. Biol Psychiatry. 2002;51:183–8.

    Article  CAS  PubMed  Google Scholar 

  276. Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol. 1996;16:80–1.

    Article  CAS  PubMed  Google Scholar 

  277. Bodkin JA, Lasser RA, Wines JD, Jr., Gardner DM, Baldessarini RJ. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry. 1997;58(4):137–45.

    Article  CAS  PubMed  Google Scholar 

  278. Spier SA. Use of bupropion with SRIs and venlafaxine. Depress Anxiety. 1998;7:73–5.

    Article  CAS  PubMed  Google Scholar 

  279. Fredman SJ, Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current “next-step” practices. J Clin Psychiatry. 2000;61(6):403–8.

    Article  CAS  PubMed  Google Scholar 

  280. Nelson JC, Mazure CM, Bowers MB, Jr., Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48(4):303–7.

    Article  CAS  PubMed  Google Scholar 

  281. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994;151(9):1372–4.

    CAS  PubMed  Google Scholar 

  282. Rothschild BS. Fluoxetine-nortiptyline therapy of treatment-resistant major depression in a geriatric patient. J Geriatr Psychiatry Neurol. 1994;7(3):137–8.

    CAS  PubMed  Google Scholar 

  283. Amsterdam JD, Garcia-Espana F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depress Anxiety. 1997;5(2):84–90.

    Article  CAS  PubMed  Google Scholar 

  284. de Montigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry. 1981;138:252–6.

    Article  PubMed  Google Scholar 

  285. de Montigny C, Cournoyer G, Morissette R, Langlois R, Caille G. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepresant drugs and lithium ion on the serotonin system. Arch Gen Psychiatry. 1983;40(12):1327–34.

    Article  PubMed  Google Scholar 

  286. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993;50(5):387–93.

    Article  CAS  PubMed  Google Scholar 

  287. Gray EG. Severe depression: a patient’s thoughts. Br J Psychiatry. 1983;143:319–22.

    Article  CAS  PubMed  Google Scholar 

  288. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression. Arch Gen Psychiatry. 1983;40(12):1335–42.

    Article  CAS  PubMed  Google Scholar 

  289. Graham PM. Drug combination for chronic depression. Br J Psychiatry. 1984;145:214.

    Article  CAS  PubMed  Google Scholar 

  290. Pope HG, Jr., McElroy SL, Nixon RA. Possible synergism between fluoxetine and lithium in refractory depression. Am J Psychiatry. 1988;145:1292–4.

    PubMed  Google Scholar 

  291. Katona CL, Abou-Saleh MT, Harrison DA, Nairac BA, Edwards DR, Lock T, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry. 1995;166(1):80–6.

    Article  CAS  PubMed  Google Scholar 

  292. Bauer M, Zaninelli R, Muller-Oerlinghausen B, Meister W. Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study.J Psychopharmacol. 1999;19(2):164–71.

    Article  CAS  Google Scholar 

  293. Peterson EA, Nelson K. How to meet your clients’ spiritual needs. J Psychosoc Nurs Ment Health Serv. 1987;25(5):34–9.

    CAS  PubMed  Google Scholar 

  294. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999;60(4):256–9.

    Article  CAS  PubMed  Google Scholar 

  295. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980–91.

    Article  PubMed  Google Scholar 

  296. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, et al. Effectiveness of St John’s wort in major depression: a randomized controlled trial. JAMA. 2001;285(15):1978–86.

    Article  CAS  PubMed  Google Scholar 

  297. Papakostas GI. Augmentation strategies in the treatment of major depressive disorder. Examining the evidence on augmentation with atypical antipsychotics. CNS Spectr. 2007;12(12 Suppl 22):10–2.

    PubMed  Google Scholar 

  298. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843–53.

    Article  CAS  PubMed  Google Scholar 

  299. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156–65.

    Article  CAS  PubMed  Google Scholar 

  300. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Astrom M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 2009;70(4):526–39.

    Article  CAS  PubMed  Google Scholar 

  301. Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry. 2005;66(Suppl 8):30–40.

    CAS  PubMed  Google Scholar 

  302. Jacobsen FM. A possible augmentation of antidepressant response by buspirone. J Clin Psychiatry. 1991;52:217–20.

    CAS  PubMed  Google Scholar 

  303. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry. 1993;54:269–71.

    CAS  PubMed  Google Scholar 

  304. Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin selective reuptake inhibitors in severe treatment-refractory depression. S Afr Med J. 1997;87(Suppl 4):534–7.

    CAS  PubMed  Google Scholar 

  305. Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol. 1998;18:465–9.

    Article  CAS  PubMed  Google Scholar 

  306. Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry. 2001;62(6):448–52.

    Article  CAS  PubMed  Google Scholar 

  307. Landen M, Bjorling G, Agren H, Fahlen T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry. 1998;59(12):664–8.

    Article  CAS  PubMed  Google Scholar 

  308. Patrick KS, Mueller RA, Gualtieri CT, Breese GR. Pharmacokinetics and actions of methylphenidate. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven; 1987. p. 1387–95.

    Google Scholar 

  309. Wharton RN, Perel JM, Dayton PG, Malitz SM. A potential clinical use for methylphenidate with tricyclic antidepressants. Am J Psychiatry. 1971;127:1619–25.

    CAS  PubMed  Google Scholar 

  310. Fawcett JA, Kravitz HM, Zajecka JM, Schaff MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Psychopharmacol. 1991;11:127–32.

    CAS  Google Scholar 

  311. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry. 1996;57(2):72–6.

    CAS  PubMed  Google Scholar 

  312. Bader GM, Hawley JM, Short DD. Venlafaxine augmentation with methylphenidate for treatment-refractory depression: a case report. J Clin Psychopharmacol. 1998;18(3):255–6.

    Article  CAS  PubMed  Google Scholar 

  313. Masand PS, Anand VS, Tanquary JF. Psychostimulant augmentation of second generation antidepressants: a case series. Depress Anxiety. 1998;7:89–91.

    Article  CAS  PubMed  Google Scholar 

  314. Postolache TT, Rosenthal RN, Hellerstein DJ, Aromin R, Kelton GM, Muran JC, et al. Early augmentation of sertraline with methylphenidate. J Clin Psychiatry. 1999;60(2):123–4.

    Article  CAS  PubMed  Google Scholar 

  315. Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry. 2001;9(3):298–303.

    CAS  PubMed  Google Scholar 

  316. Naranjo CA, Tremblay LK, Busto UE. The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:781–823.

    Article  CAS  PubMed  Google Scholar 

  317. Tremblay LK, Naranjo CA, Cardenas L, Herrmann N, Busto UE. Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch Gen Psychiatry. 2002;59(5):409–16.

    Article  PubMed  Google Scholar 

  318. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry. 2000;61(5):378–81.

    Article  CAS  PubMed  Google Scholar 

  319. Markovitz PJ, Wagner S. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy [letter]. J Clin Psychopharmacol. 2003;23(2):207–9.

    Article  PubMed  Google Scholar 

  320. Prange AJ, Jr., et al. Hormonal alteration of imipramine response: a review. In: Sachar EJ, editor. Hormones, behavior, and psychopathology. New York: Raven; 1976.

    Google Scholar 

  321. Wheatley D. Potentiation of amitriptyline by thyroid hormone. Arch Gen Psychiatry. 1972;26:229–33.

    Article  CAS  PubMed  Google Scholar 

  322. Tsutsui S, Yamazaki Y, Namba T, Tsushima M. Combined therapy of T3, and antidepressants in depression. J Int Med Res. 1979;7(2):138–46.

    CAS  PubMed  Google Scholar 

  323. Earle BV. Thyroid hormone and tricyclic antidepressants in resistant depressions. Am J Psychiatry. 1970;126(11):1667–9.

    CAS  PubMed  Google Scholar 

  324. Ogura C, Okuma T, Uchida Y, Imai S, Yogi H. Combined thyroid (triodothyronine)-tricyclic antidepressant treatment in depressive states. Folia Psychiatr Neurol Jpn. 1974;28(3):179–86.

    CAS  PubMed  Google Scholar 

  325. Goodwin FK, Prange A, Post R, Muscettola G, Lipton MA. Potentiation of antidepresant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry. 1982;139(1):34–8.

    CAS  PubMed  Google Scholar 

  326. Joffe RT, Levitt AJ, Bagby RM, MacDonald C, Singer W. Predictors of response to lithium and triiodothyronine: augmentation of antidepressants in tricyclic non-responders. Br J Psychiatry. 1993;163:574–8.

    Article  CAS  PubMed  Google Scholar 

  327. Crowe D, Collins JP, Rosse RB. Thyroid hormone supplementation of fluoxetine treatment [letter]. J Clin Psychopharmacol. 1990;10:150–1.

    Article  CAS  PubMed  Google Scholar 

  328. Gupta S, Masand P, Tanquary JF. Thyroid hormone supplementation of fluoxetine in the treatment of major depression. Br J Psychiatry. 1991;159:866–7.

    Article  CAS  PubMed  Google Scholar 

  329. Joffe RT. Triiodothyronine potentiation of fluoxetine in depressed patients. Can J Psychiatry. 1992;37:48–50.

    CAS  PubMed  Google Scholar 

  330. Gitlin MJ, Weiner H, Farbanks L, Hershman JM, Friedfeld N. Failure of T3 to potentiate tricyclic antidepressant response. J Affect Disord. 1987;13(3):267–72.

    Article  CAS  PubMed  Google Scholar 

  331. Targum SD, Greenberg RD, Harmon RL, Kessler K, Salerian AJ, Fram DH. Thyroid hormone and the TRH stimulation test in refractory depression. J Clin Psychiatry. 1984;45(8):345–6.

    CAS  PubMed  Google Scholar 

  332. Spoov J, Lahdelma L. Should thyroid augmentation precede lithium augmentation – a pilot study. J Affect Disord. 1998;49:235–9.

    Article  CAS  PubMed  Google Scholar 

  333. Bauer M, Hellweg R, Graf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology. 1998;18(6):444–55.

    Article  CAS  PubMed  Google Scholar 

  334. Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry. 2001;158(10):1617–22.

    Article  CAS  PubMed  Google Scholar 

  335. Pope HG, Jr., Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(1):105–11.

    Article  PubMed  Google Scholar 

  336. de Novaes Soares C, Almeida O, Joffe H, Cohen LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58(6):529–34.

    Google Scholar 

  337. Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, Murphy JH, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol. 2000;183:414–20.

    Article  CAS  PubMed  Google Scholar 

  338. Rasgon NL, Altshuler LL, Fairbanks LA, Dunkin JJ, Davtyan C, Elman S, et al. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry. 2002;63(Suppl 7):745–8.

    Google Scholar 

  339. Smith RN, Studd JW, Zamblera D, Holland EF. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol. 1995;102:475–84.

    Article  CAS  PubMed  Google Scholar 

  340. Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996;347:930–3.

    Article  CAS  PubMed  Google Scholar 

  341. Ahokas A, Kaukoranta J, Aito M. Effect of oestradiol on postpartum depression. Psychopharmacology. 1999;146:108–10.

    Article  CAS  PubMed  Google Scholar 

  342. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynecol. 1977;4:31–47.

    CAS  Google Scholar 

  343. Coope J. Is oestrogen therapy effective in the treatment of menopausal depression? J R Coll Gen Pract. 1981;31:134–40.

    CAS  PubMed  Google Scholar 

  344. Pearce J, Hawton K, Blake F, Barlow D, Rees M, Fagg J, et al. Psychological effects of continuation versus discontinuation of hormone replacement therapy by estrogen implants: a placebo-controlled study. J Psychosom Res. 1997;42:177–86.

    Article  CAS  PubMed  Google Scholar 

  345. Epperson CN, Wisner KL, Yamamoto B. Gonadal steroids in the treatment of mood disorders. Psychosom Med. 1999;61(5):676–97.

    CAS  PubMed  Google Scholar 

  346. Montgomery JC, Brincat M, Tapp A, Appleby L, Versi E, Fenwick PBC, et al. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet. 1987;1:297–9.

    Article  CAS  PubMed  Google Scholar 

  347. Kaliber EL, Broverman DM, Vogel W, Kobayashi Y. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry. 1979;36:550–4.

    Article  Google Scholar 

  348. Haines CJ, Yim SF, Chung TKH, Lam CWK, Lau EWC, Ng MHL, et al. A prospective, randomized, placebo-controlled study of the dose effect of oral oestradiol on menopausal symptoms, psychological well being, and quality of life in postmenopausal Chinese women. Maturitas. 2003;44:207–14.

    Article  CAS  PubMed  Google Scholar 

  349. Schneider LS, Small GW, Hamilton SH, Bystritsky A, Nemeroff CB, Meyers BS. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Am J Geriatr Psychiatry. 1997;5:97–106.

    CAS  PubMed  Google Scholar 

  350. Sheline YI, Pieper CF, Barch DM, Welsh-Boehmer K, McKinstry RC, MacFall JR, et al. Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Arch Gen Psychiatry. 2010;67(3):277–85.

    Article  PubMed  Google Scholar 

  351. Gambacciani M, Monteleone P, Sacco A, Genazzani AR. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab. 2003;17(1):139–47.

    Article  CAS  PubMed  Google Scholar 

  352. Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349(6):535–45.

    Article  CAS  PubMed  Google Scholar 

  353. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003;289(24):3254–63.

    Article  CAS  PubMed  Google Scholar 

  354. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6):523–34.

    Article  CAS  PubMed  Google Scholar 

  355. Rogoz Z, Skuza G, Daniel WA, Wojcikowski J, Dudek D, Wrobel A. Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol Rep. 2007;59(6):778–84.

    CAS  PubMed  Google Scholar 

  356. Stryjer R, Strous RD, Shaked G, Bar F, Feldman B, Kotler M, et al. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol. 2003;18(2):93–6.

    Article  PubMed  Google Scholar 

  357. Schultz V, Haensel R, Tyler VE, editors. Rational phytotherapy. 3rd ed. Berlin: Springer; 1998.

    Google Scholar 

  358. Assemi M. Herbs affecting the central nervous system: gingko, kava, St. John’s wort, and valerian. Clin Obstet Gynecol. 2001;44(4):824–35.

    Article  CAS  PubMed  Google Scholar 

  359. De Smet P. Herbal remedies. N Engl J Med. 2002;347(25):2046–56.

    Article  PubMed  Google Scholar 

  360. Bilia AR, Gallori S, Vincieri FF. St. John’s wort and depression: efficacy, safety and tolerability-an update. Life Sci. 2002;70(26):3077–96.

    Article  CAS  PubMed  Google Scholar 

  361. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ. 1999;319(7224):1534–8.

    Article  CAS  PubMed  Google Scholar 

  362. Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John’s Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med. 2002;136(1):42–53.

    PubMed  Google Scholar 

  363. Woelk H. Comparison of St John’s wort and imipramine for treating depression: randomised controlled trial. BMJ. 2000;321(7260):536–9.

    Article  CAS  PubMed  Google Scholar 

  364. Gaster B, Holroyd J. St John’s wort for depression: a systematic review. Arch Intern Med. 2000;160(2):152–6.

    Article  CAS  PubMed  Google Scholar 

  365. Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John’s wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002;159(8):1361–6.

    Article  CAS  PubMed  Google Scholar 

  366. Lantz MS, Buchalter E, Giambanco V. St. John’s wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatr Neurol. 1999;12(1):7–10.

    Article  CAS  Google Scholar 

  367. Prost N, Tichadou L, Rodor F, Nguyen N, David JM, Jean-Pastor MJ. [St. Johns wort-venlafaxine interaction]. Presse Med. 2000;29(23):1285–6.

    CAS  PubMed  Google Scholar 

  368. Perloff MD, von Moltke LL, Stormer E, Shader RI, Greenblatt DJ. Saint John’s wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol. 2001;134(8):1601–8.

    Article  CAS  PubMed  Google Scholar 

  369. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol. 2002;54(4):349–56.

    Article  CAS  PubMed  Google Scholar 

  370. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St. John’s wort and cyclosporine. Ann Pharmacother. 2000;34(9):1013–6.

    Article  CAS  PubMed  Google Scholar 

  371. Barone GW, Gurley BJ, Ketel BL, Abul-Ezz SR. Herbal supplements: a potential for drug interactions in transplant recipients. Transplantation. 2001;71(2):239–41.

    Article  CAS  PubMed  Google Scholar 

  372. Yue QY, Bergquist C, Gerden B. Safety of St John’s wort (Hypericum perforatum). Lancet. 2000;355(9203):576–7.

    Article  CAS  PubMed  Google Scholar 

  373. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther. 2001;70(4):317–26.

    CAS  PubMed  Google Scholar 

  374. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther. 1999;66(4):338–45.

    Article  CAS  PubMed  Google Scholar 

  375. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999;156(5):675–82.

    CAS  PubMed  Google Scholar 

  376. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John’s wort for depression--an overview and meta-analysis of randomised clinical trials. BMJ. 1996;313(7052):253–8.

    Article  CAS  PubMed  Google Scholar 

  377. Kasper S, Dienel A. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials. Psychopharmacology (Berl). 2002;164(3):301–8.

    Article  CAS  Google Scholar 

  378. Spira JL. Comparison of St John’s Wort and imipramine. Study design casts doubt on value of St John’s wort in treating depression. BMJ. 2001;322(7284):493; author reply 4.

    Google Scholar 

  379. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287(14):1807–14.

    Google Scholar 

  380. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002;76(5):1158S–61S.

    CAS  PubMed  Google Scholar 

  381. Bell KM, Potkin SG, Carreon D, Plon L. S-adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurol Scand Suppl. 1994;154:15–8.

    Article  CAS  PubMed  Google Scholar 

  382. Bressa GM. S-adenoxyl-methionine (SAMe) as antidepressant: metanalysis of clinical studies. Acta Neurol Scand. 1994;154:7–14.

    Article  CAS  Google Scholar 

  383. Pancheri P, Racagni G, Delle Chiaie R, Popoli M. Recent experimental and clnical findings on the efficacy and safety of ademetionine in the pharmacological treatment of depression. G Ital Psicopat. 1997;3:1–23.

    Google Scholar 

  384. Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr. 2002;76(5):1172S–6S.

    Google Scholar 

  385. Fava M, Giannelli A, Rapisarda V, Patralia A, Guaraldi GP. Rapidity of onset of the antidepressant effect of parental S-adenosyl-L-methionine. Psychiatr Res. 1995;56:295–7.

    Article  CAS  Google Scholar 

  386. Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry. 2009;70(Suppl 5):18–22.

    Article  CAS  PubMed  Google Scholar 

  387. Hibbeln JR. Fish consumption and major depression. Lancet. 1998;351(9110):1213.

    Article  CAS  PubMed  Google Scholar 

  388. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord. 1996;38(1):35–46.

    Article  CAS  PubMed  Google Scholar 

  389. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord. 1998;48(2–3):149–55.

    Article  CAS  PubMed  Google Scholar 

  390. Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinic symptoms of depression. Lipids. 1996;31(Suppl):157–61.

    Article  Google Scholar 

  391. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. 2002;59:913–9.

    Article  CAS  PubMed  Google Scholar 

  392. Calabrese JR, Rapport DJ, Shelton MD. Fish oils and bipolar disorder: a promising but untested treatment [commentary]. Arch Gen Psychiatry. 1999;56(5):413–4.

    Article  CAS  PubMed  Google Scholar 

  393. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999;56:407–12.

    Article  CAS  PubMed  Google Scholar 

  394. Stoll AL, Marangell LB. In reply [commentary]. Arch Gen Psychiatry. 1999;56(5):415–6.

    Article  Google Scholar 

  395. Freeman MP. Omega-3 fatty acids in major depressive disorder. J Clin Psychiatry. 2009;70(Suppl 5):7–11.

    Article  CAS  PubMed  Google Scholar 

  396. Waal HJ. Propranolol-induced depression. Br Med J. 1967;2(5543):50.

    Article  CAS  PubMed  Google Scholar 

  397. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288(3):351–7.

    Article  CAS  PubMed  Google Scholar 

  398. Steffensmeier JJ, Ernst ME, Kelly M, Hartz AJ. Do randomized controlled trials always trump case reports? A second look at propranolol and depression. Pharmacotherapy. 2006;26(2):162–7.

    Article  CAS  PubMed  Google Scholar 

  399. Dunn NR, Freemantle SN, Mann RD. Cohort study on calcium channel blockers, other cardiovascular agents, and the prevalence of depression. Br J Clin Pharmacol. 1999;48(2):230–3.

    Article  CAS  PubMed  Google Scholar 

  400. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7(5):478–84.

    Article  CAS  PubMed  Google Scholar 

  401. Ciraulo DA, Shader RI, Greenblatt DJ, Creelman WL, editors. Drug interactions in psychiatry. 2nd ed. Baltimore, MD: Williams & Wilkins; 1995.

    Google Scholar 

  402. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol. 1999;19(5 Suppl 1):23S–35S.

    Article  CAS  PubMed  Google Scholar 

  403. Burke WJ, McArthur-Miller DA. Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder. J Clin Psychiatry. 2001;62(Suppl 22):38–42.

    Google Scholar 

  404. Dinan TG. Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder. J Clin Psychiatry. 2001;62(Suppl 22):48–52.

    Google Scholar 

  405. Wagstaff AJ, Goa KL. Once-weekly fluoxetine. Drugs. 2001;61(15):2221–30.

    Article  CAS  PubMed  Google Scholar 

  406. de Klerk E. Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry. 2001;62(Suppl 22):43–7.

    PubMed  Google Scholar 

  407. Shulman KI, Walker SE, MacKenzie S, Knowles S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989;9(6):397–402.

    Article  CAS  PubMed  Google Scholar 

  408. Shulman KI, Walker SE. Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry. 1999;60(3):191–3.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to acknowledge the contributions of Lucy Tsirulnik-Barts, MD, who was a co-author on this chapter for the first edition.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Boston University School of Medicine, 720 Harrison Avenue, Suite 914, Boston, MA, USA

    Domenic A. Ciraulo

Authors
  1. Domenic A. Ciraulo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard I. Shader
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David J. Greenblatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Domenic A. Ciraulo .

Editor information

Editors and Affiliations

  1. School of Medicine, Div. Psychiatry, Boston University, Harrison Ave. 720, Boston, 02118, Massachusetts, USA

    Domenic A. Ciraulo

  2. School of Medicine, Dept. Pharmacology &, Tufts University, Harrison Ave. 136, Boston, 02111, Massachusetts, USA

    Richard Irwin Shader

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Ciraulo, D.A., Shader, R.I., Greenblatt, D.J. (2011). Clinical Pharmacology and Therapeuticsof Antidepressants. In: Ciraulo, D., Shader, R. (eds) Pharmacotherapy of Depression. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-435-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-435-7_2

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60327-434-0

  • Online ISBN: 978-1-60327-435-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation